Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of trimethoprim against Borrelia burgdorferi.

Literature DB >> 9248750

In vitro activity of trimethoprim against Borrelia burgdorferi.

Abstract

A new culture medium has been developed to evaluate the activity of trimethoprim and sulfamethoxazole against Borrelia burgdorferi in vitro. In this specially modified Barbour-Stoenner-Kelly medium, in which antagonizing substances were reduced to a minimum, trimethoprim was more active against Borrelia burgdorferi than against a sensitive strain of Escherichia coli, but sulfamethoxazole was not active against Borrelia burgdorferi.

Entities: Chemical Species

Mesh：

Substances：

Year: 1997 PMID： 9248750 DOI： 10.1007/bf02471911

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

13 in total

1. Late treatment of chronic Lyme arthritis.

Authors: L M Pedersen; A Friis-Møller
Journal: Lancet Date: 1991-01-26 Impact factor: 79.321

2. Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole.

Authors: C A Bowman
Journal: Lancet Date: 1990-12-15 Impact factor: 79.321

3. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.

Authors: A Kersten; C Poitschek; S Rauch; E Aberer
Journal: Antimicrob Agents Chemother Date: 1995-05 Impact factor: 5.191

4. Evaluation of agents for use in medium for selective isolation of Lyme disease and relapsing fever Borrelia species.

Authors: M G Morshed; H Konishi; T Nishimura; T Nakazawa
Journal: Eur J Clin Microbiol Infect Dis Date: 1993-07 Impact factor: 3.267

5. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors: V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-07 Impact factor: 3.267

6. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors: K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal: Acta Derm Venereol Date: 1992-08 Impact factor: 4.437

In vitro activity of trimethoprim against Borrelia burgdorferi.

1. Late treatment of chronic Lyme arthritis.

2. Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole.

3. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.

4. Evaluation of agents for use in medium for selective isolation of Lyme disease and relapsing fever Borrelia species.

5. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

6. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

7. Antibiotics and increased temperature against Borrelia burgdorferi in vitro.

8. Roxithromycin in the treatment of Lyme disease--update and perspectives.

9. Standardization of medium for culturing Lyme disease spirochetes.

10. Isolation and cultivation of Lyme disease spirochetes.

1. Esterases in serum-containing growth media counteract chloramphenicol acetyltransferase activity in vitro.